Press Release
May 7, 2024
Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
December 4, 2023
Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer
September 5, 2023
Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb
August 1, 2023